Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219528 · ClinicalTrials.gov registry record · Phase 4
A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
A Phase 4 study of Irritable Bowel Syndrome, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT03219528 is a Phase 4 study of Irritable Bowel Syndrome that has completed, run by University of Michigan. The registered enrollment target is 74 participants, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03219528, a Phase 4 study of Irritable Bowel Syndrome, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a highly prevalent but poorly understood condition with limited treatment options. Current therapies, including a nonabsorbable antibiotic rifaximin or diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP), show efficacy in 50% or less of patients. In this proposal, participants with IBS-D will be randomized to receive either rifaximin or low FODMAP dietary intervention.
Conditions Studied
Interventions
- OTHER Low FODMAP Diet
- DRUG Rifaximin 550 MG
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2018-02-13 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03219528
The ClinicalTrials.gov registry entry for NCT03219528 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (48% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Low FODMAP Diet is the first listed.
NCT03219528 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03219528 about?
NCT03219528 is a clinical study titled "A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing". Diarrhea-predominant irritable bowel syndrome (IBS-D) is a highly prevalent but poorly understood condition with limited treatment options. Current therapies, including a nonabsorbable antibiotic rifaximin or diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODM...
What is the current status of trial NCT03219528?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 74 participants. The study started on 2018-02-13. Estimated completion is 2024-02-28.
What conditions does trial NCT03219528 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome.
What interventions are being tested in trial NCT03219528?
The interventions under investigation include: Low FODMAP Diet (OTHER), Rifaximin 550 MG (DRUG).
Who is sponsoring clinical trial NCT03219528?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03219528 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Psyllium in Pediatric IBS
RECRUITING · Phase 2
-
Mucosal and Microbiota Changes During Acute Campylobacteriosis
RECRUITING
-
GI Alpha-Gal Study
RECRUITING · NA
-
Visible Abdominal Distension
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.